Compare ASMB & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASMB | ITIC |
|---|---|---|
| Founded | 2005 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 553.6M | 517.1M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | ITIC |
|---|---|---|
| Price | $30.81 | $256.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | ★ 150.8K | 16.7K |
| Earning Date | 11-10-2025 | 02-12-2026 |
| Dividend Yield | N/A | ★ 4.15% |
| EPS Growth | N/A | ★ 25.81 |
| EPS | N/A | ★ 19.00 |
| Revenue | $37,191,000.00 | ★ $273,864,000.00 |
| Revenue This Year | $33.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.40 |
| Revenue Growth | ★ 31.30 | 13.63 |
| 52 Week Low | $7.75 | $190.20 |
| 52 Week High | $39.71 | $288.98 |
| Indicator | ASMB | ITIC |
|---|---|---|
| Relative Strength Index (RSI) | 39.55 | 52.93 |
| Support Level | $31.73 | $244.08 |
| Resistance Level | $34.69 | $258.45 |
| Average True Range (ATR) | 2.07 | 5.82 |
| MACD | -0.36 | 1.06 |
| Stochastic Oscillator | 2.50 | 80.75 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.